Article Details

PDS Biotech VERSATILE-002 Phase 2 Clinical Trial Meets Primary Study Endpoints ... - Morningstar

Retrieved on: 2024-05-09 22:35:32

Tags for this article:

Click the tags to see associated articles and topics

PDS Biotech VERSATILE-002 Phase 2 Clinical Trial Meets Primary Study Endpoints ... - Morningstar. View article details on hiswai:

Excerpt

The immune checkpoint inhibitor (ICI) naïve cohort (n=53) met its primary endpoint of best overall response (BOR). BOR by investigator assessment is ...

Article found on: www.morningstar.com

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up
Book a Demo